Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Pharmacokinetics and Pharmacodynamics in Drug Development

  • Simon Pacey
  • Debashis Sarker
  • Paul Workman
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_4501-2

Definition

Pharmacokinetics

Pharmacokinetics (PK) is the study of how a drug is absorbed, distributed, metabolized, and excreted over time.

Pharmacodynamics

Pharmacodynamics (PD) is the study of how a drug affects its target(s) in a dose- and time-dependent fashion.

Characteristics

To maximize the chance of successful drug development, a comprehensive knowledge of the compound under investigation is required. Assuming the drug target has been correctly selected, drug efficacy requires delivery into the patient such that adequate drug concentration is achieved within the plasma and tumor (measured by PK studies) to effect target modulation (measured by PD studies) resulting in anticancer effect(s). These principles have been incorporated into a pharmacological audit trail consisting of a series of questions that should be addressed during drug design and development. These can be summarized as:
  • Is the drug target expressed in the tumor of interest?

  • Are adequate plasma and tumor drug...

Keywords

Epidermal Growth Factor Receptor HSP90 Inhibition Client Protein Target Modulation Human Tumor Xenograft 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Banerji U, O’Donnell A, Scurr M et al (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152–4161CrossRefPubMedGoogle Scholar
  2. Garrett MD, Walton MI, McDonald E et al (2003) The contemporary drug development process: advances and challenges in preclinical and clinical development. Prog Cell Cycle Res 5:145–158PubMedGoogle Scholar
  3. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715CrossRefPubMedGoogle Scholar
  4. Sarker D, Workman P (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 96:213–268CrossRefPubMedGoogle Scholar
  5. Sarker D, Pacey S, Workman P (2007) Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. Biomark Med 1:399–417CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Cancer Research UK Center for Cancer TherapeuticsThe Institute of Cancer ResearchSutton, SurreyUK